GET DAILY SIGNALSSeres Therapeutics (MCRB) Swings to Q3 Profit on One-Time Gain, Revenue Miss Highlights Pipeline Shift
Key Takeaways
- Seres Therapeutics reported third quarter 2025 net income from continuing operations of $8.2 million, a sharp swing from a $51.0 million net loss in the same period last year.
- The profit was driven by a $27.2 million gain on the sale of VOWST, including a $25 million installment payment from Nestlé, rather than by underlying operating performance.
- Revenue of roughly $0.35 million came in well below consensus estimates near $7.8 million, reflecting the company's shift to a clinical-stage model after divesting VOWST.
- Research and development (R&D) expenses fell to $12.6 million and general and administrative (G&A) expenses to $9.5 million, helped by a 25% workforce reduction.
- Cash and cash equivalents of $47.6 million are expected to fund operations through the second quarter of 2026.
Why This Quarter Matters for Seres
Seres Therapeutics (MCRB) is now a clinical-stage live biotherapeutics company following the September 2024 sale of its FDA-approved product VOWST to Nestlé Health Science. Its lead candidate is SER-155, and with no commercial products left, earnings reports like this one focus more on spending discipline, cash runway, and progress toward the next clinical step than on top-line revenue. From what I see, the key signals here involve cost control and the ability to reach important milestones that could influence valuation.
Breaking Down the Reported Numbers
MCRB posted net income from continuing operations of $8.2 million for the third quarter of 2025, compared with a net loss from continuing operations of $51.0 million in the prior-year quarter. The result included a $22.5 million loss from operations offset by the $27.2 million gain on the sale of VOWST, which included the expected $25 million installment from Nestlé. Diluted EPS from continuing operations came in at $0.94, versus a loss of $6.69 per share a year earlier.
Revenue totaled approximately $0.35 million, well below consensus estimates near $7.8 million, as the company no longer records product sales after the VOWST divestiture. R&D expenses declined to $12.6 million from $16.5 million, and G&A expenses fell to $9.5 million from $12.7 million, aided by the 25% workforce reduction. Cash and cash equivalents stood at $47.6 million as of September 30, 2025, which management expects will support operations through the second quarter of 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Focus
Shares of MCRB moved lower after the November 5, 2025 announcement. Investors appeared to focus on the one-time nature of the profit and the revenue shortfall rather than the headline EPS beat. Sentiment stays measured, with attention now on whether the company can raise the capital needed to start the SER-155 Phase 2 study. The cash runway extends only through the second quarter of 2026, and study initiation remains funding dependent.
Key Catalysts Ahead
The main driver for MCRB remains the SER-155 program, an oral live biotherapeutic aimed at preventing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant. Phase 1b data showed a 77% relative risk reduction versus placebo and supported Breakthrough Therapy designation from the FDA. Management is finalizing the Phase 2 protocol after FDA feedback and anticipates meaningful interim results roughly 12 months after study start, assuming funding is secured. A $3.6 million CARB-X grant supports development of an oral liquid formulation that could expand access. Other items worth watching include early 2026 data from a Memorial Sloan Kettering investigator-sponsored trial in immune checkpoint-related enterocolitis, potential R&D partnerships, and any additional steps to extend the cash runway.
Using Tickeron’s AI Tools in My Research
When analyzing clinical-stage names like this, I find it helpful to run quick scans with Tickeron’s AI-powered tools to compare valuation metrics, volatility, and technical patterns against peers. The AI Screener lets me filter efficiently by industry, market cap, and performance signals, which adds context without replacing fundamental work. It is one of the resources I turn to when building a broader view of how a stock like MCRB fits into the current market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MCRB in upward trend: price may jump up because it broke its lower Bollinger Band on October 27, 2026
MCRB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 46 of 52 cases where MCRB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MCRB's RSI Oscillator exited the oversold zone, 25 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for MCRB just turned positive on October 29, 2026. Looking at past instances where MCRB's MACD turned positive, the stock continued to rise in 37 of 42 cases over the following month. The odds of a continued upward trend are 88%.
Following a +10.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where MCRB advanced for three days, in 199 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCRB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MCRB entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.570) is normal, around the industry mean (3.051). P/E Ratio (-0.810) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (21.008) is also within normal values, averaging (439.647).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. MCRB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MCRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel treatments for diseases related to the human microbiome
Industry Biotechnology
Advertisement